Published in Mol Endocrinol on September 13, 2007
One Week Comparison Study of PTH and PTHrP Infusions | NCT01333267
Comparison Study of PTHrP and PTH to Treat Osteoporosis | NCT00853723
Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol (2009) 3.03
PTH and PTHrP signaling in osteoblasts. Cell Signal (2009) 1.69
Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci U S A (2013) 1.68
Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab (2012) 1.54
Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A (2008) 1.45
Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J Biol Chem (2009) 1.36
Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci (2010) 1.30
Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab (2012) 1.13
Noncanonical GPCR signaling arising from a PTH receptor-arrestin-Gβγ complex. Proc Natl Acad Sci U S A (2013) 1.08
Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc Natl Acad Sci U S A (2008) 1.08
Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep (2013) 1.06
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. Mol Endocrinol (2014) 1.04
Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab (2010) 1.03
Endosomal generation of cAMP in GPCR signaling. Nat Chem Biol (2014) 1.03
Endosomal GPCR signaling turned off by negative feedback actions of PKA and v-ATPase. Nat Chem Biol (2014) 1.01
Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology (2015) 1.00
PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat Rev Endocrinol (2015) 0.98
Acute down-regulation of sodium-dependent phosphate transporter NPT2a involves predominantly the cAMP/PKA pathway as revealed by signaling-selective parathyroid hormone analogs. J Biol Chem (2010) 0.95
Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci (2012) 0.95
A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover. J Bone Miner Res (2011) 0.94
Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnover. J Clin Endocrinol Metab (2010) 0.88
Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats. Calcif Tissue Int (2016) 0.87
Time-resolved fluorescence ligand binding for G protein-coupled receptors. Nat Protoc (2013) 0.87
Mechanical stimulus alters conformation of type 1 parathyroid hormone receptor in bone cells. Am J Physiol Cell Physiol (2009) 0.86
Theme and variations on kinetics of GPCR activation/deactivation. J Recept Signal Transduct Res (2010) 0.84
PTH and PTH antagonist induce different conformational changes in the PTHR1 receptor. J Bone Miner Res (2009) 0.84
GPCR Signaling and Trafficking: The Long and Short of It. Trends Endocrinol Metab (2016) 0.83
International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors. Pharmacol Rev (2015) 0.83
The C-terminal fragment of parathyroid hormone-related peptide promotes bone formation in diabetic mice with low-turnover osteopaenia. Br J Pharmacol (2011) 0.82
Structural basis for antibody discrimination between two hormones that recognize the parathyroid hormone receptor. J Biol Chem (2009) 0.81
Eliminating phosphorylation sites of the parathyroid hormone receptor type 1 differentially affects stimulation of phospholipase C and receptor internalization. Am J Physiol Endocrinol Metab (2008) 0.81
Abaloparatide. Clin Cases Miner Bone Metab (2016) 0.79
Chemistry as an expanding resource in protein science: fully synthetic and fully active human parathyroid hormone-related protein (1-141). Angew Chem Int Ed Engl (2012) 0.79
Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol (2015) 0.78
The N- and C-terminal domains of parathyroid hormone-related protein affect differently the osteogenic and adipogenic potential of human mesenchymal stem cells. Exp Mol Med (2010) 0.78
PTH Signaling and Epigenetic Control of Bone Remodeling. Curr Mol Biol Rep (2016) 0.76
Sustained signalling by PTH modulates IP3 accumulation and IP3 receptors through cyclic AMP junctions. J Cell Sci (2014) 0.76
Translating in vitro ligand bias into in vivo efficacy. Cell Signal (2017) 0.76
Emerging Therapies for Osteoporosis. Endocrinol Metab (Seoul) (2015) 0.75
Mechanisms of action of islet neogenesis-associated protein: comparison of the full-length recombinant protein and a bioactive peptide. Am J Physiol Endocrinol Metab (2012) 0.75
Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism. Nat Commun (2016) 0.75
Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus (2017) 0.75
A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem (1980) 6.06
Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol (2003) 2.84
Parathyroid hormone-responsive clonal cell lines from rat osteosarcoma. Endocrinology (1980) 2.46
PTHrP and skeletal development. Ann N Y Acad Sci (2006) 2.43
Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res (2005) 2.19
Principles: receptor theory in pharmacology. Trends Pharmacol Sci (2004) 2.18
Maximal rate and nucleotide dependence of rhodopsin-catalyzed transducin activation: initial rate analysis based on a double displacement mechanism. J Biol Chem (2000) 1.93
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest (2005) 1.88
Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun (2005) 1.78
Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci U S A (2005) 1.63
Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2003) 1.42
Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol Endocrinol (2005) 1.36
Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res (2005) 1.34
Initial characterization of PTH-related protein gene-driven lacZ expression in the mouse. J Bone Miner Res (2005) 1.33
Parathyroid hormone receptor recycling: role of receptor dephosphorylation and beta-arrestin. Mol Endocrinol (2002) 1.28
Phosphorylation of the receptor for PTH and PTHrP is required for internalization and regulates receptor signaling. Mol Endocrinol (2002) 1.21
Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem (2002) 1.21
The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation. Biochemistry (2006) 1.17
Evaluating the signal transduction mechanism of the parathyroid hormone 1 receptor. Effect of receptor-G-protein interaction on the ligand binding mechanism and receptor conformation. J Biol Chem (2000) 1.13
Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest (2005) 1.13
A highly effective dominant negative alpha s construct containing mutations that affect distinct functions inhibits multiple Gs-coupled receptor signaling pathways. J Biol Chem (2002) 1.11
Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J Endocrinol (2000) 1.10
Dual regulation of the parathyroid hormone (PTH)/PTH-related peptide receptor signaling by protein kinase C and beta-arrestins. Endocrinology (2002) 1.06
Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. J Biol Chem (2001) 1.03
Enhanced activity in parathyroid hormone-(1-14) and -(1-11): novel peptides for probing ligand-receptor interactions. Endocrinology (2001) 1.02
Dual signaling and ligand selectivity of the human PTH/PTHrP receptor. J Bone Miner Res (1999) 1.01
Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int (2005) 1.00
Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor. J Biol Chem (2004) 0.99
Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands. Peptides (2003) 0.95
Non-homologous sequences of parathyroid hormone and the parathyroid hormone related peptide bind to a common receptor on ROS 17/2.8 cells. Endocrinology (1989) 0.93
Role of amino acid side chains in region 17-31 of parathyroid hormone (PTH) in binding to the PTH receptor. J Biol Chem (2006) 0.93
Characterization and agonist-induced down-regulation of parathyroid hormone receptors in clonal rat osteosarcoma cells. Endocrinology (1988) 0.93
Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist. J Biol Chem (1996) 0.92
Measurement of agonist and antagonist ligand-binding parameters at the human parathyroid hormone type 1 receptor: evaluation of receptor states and modulation by guanine nucleotide. J Pharmacol Exp Ther (1999) 0.89
The complex regulation of receptor-coupled G-proteins. Adv Enzyme Regul (1997) 0.86
Identification of a Mg(2+)- and guanyl nucleotide-dependent glucagon receptor cycle by use of permeabilized canine hepatocytes. J Biol Chem (1992) 0.82
Parathyroid hormone (PTH)-PTH-related peptide hybrid peptides reveal functional interactions between the 1-14 and 15-34 domains of the ligand. J Biol Chem (1995) 0.81
The bovine renal parathyroid hormone (PTH) receptor has equal affinity for two different amino acid sequences: the receptor binding domains of PTH and PTH-related protein are located within the 14-34 region. Endocrinology (1990) 0.80
Histidine at position 5 is the specificity "switch" between two parathyroid hormone receptor subtypes. Endocrinology (1996) 0.80
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab (2009) 3.81
A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods (2005) 3.11
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab (2002) 3.06
Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol (2009) 3.03
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.98
Retromer terminates the generation of cAMP by internalized PTH receptors. Nat Chem Biol (2011) 1.88
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res (2002) 1.79
Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun (2005) 1.78
Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci U S A (2013) 1.68
Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci U S A (2005) 1.63
Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor. Proc Natl Acad Sci U S A (2012) 1.50
Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors. Trends Pharmacol Sci (2008) 1.46
Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A (2008) 1.45
Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest (2007) 1.44
Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J Biol Chem (2009) 1.36
Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol Endocrinol (2005) 1.36
Progress, paradox, and potential: parathyroid hormone research over five decades. Ann N Y Acad Sci (2007) 1.31
Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci (2010) 1.30
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Cell migration is regulated by platelet-derived growth factor receptor endocytosis. Mol Cell Biol (2009) 1.15
Molecular basis of partial agonism at the neurotransmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer. J Biol Chem (2006) 1.14
Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem (2013) 1.12
Noncanonical GPCR signaling arising from a PTH receptor-arrestin-Gβγ complex. Proc Natl Acad Sci U S A (2013) 1.08
The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab (2009) 1.07
Lighting up multiprotein complexes: lessons from GPCR oligomerization. Trends Biotechnol (2010) 1.06
Dual regulation of the parathyroid hormone (PTH)/PTH-related peptide receptor signaling by protein kinase C and beta-arrestins. Endocrinology (2002) 1.06
Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor. Mol Endocrinol (2003) 1.04
Monitoring receptor signaling by intramolecular FRET. Curr Opin Pharmacol (2007) 1.03
Endosomal generation of cAMP in GPCR signaling. Nat Chem Biol (2014) 1.03
Sympathetic control of bone mass regulated by osteopontin. Proc Natl Acad Sci U S A (2011) 0.99
Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor. J Biol Chem (2004) 0.99
Kinetic analysis of G protein-coupled receptor signaling using fluorescence resonance energy transfer in living cells. Adv Protein Chem (2007) 0.97
Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci (2012) 0.95
Acute down-regulation of sodium-dependent phosphate transporter NPT2a involves predominantly the cAMP/PKA pathway as revealed by signaling-selective parathyroid hormone analogs. J Biol Chem (2010) 0.95
Dynamic Na+-H+ exchanger regulatory factor-1 association and dissociation regulate parathyroid hormone receptor trafficking at membrane microdomains. J Biol Chem (2011) 0.94
Role of amino acid side chains in region 17-31 of parathyroid hormone (PTH) in binding to the PTH receptor. J Biol Chem (2006) 0.93
Amino-terminal parathyroid hormone fragment analogs containing alpha,alpha-di-alkyl amino acids at positions 1 and 3. J Bone Miner Res (2004) 0.90
Effects of the renal medullary pH and ionic environment on vasopressin binding and signaling. Kidney Int (2008) 0.88
Formation of a ternary complex among NHERF1, beta-arrestin, and parathyroid hormone receptor. J Biol Chem (2010) 0.87
Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines. Endocr Pract (2009) 0.87
Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the future. J Bone Miner Res (2002) 0.87
Extra-long Gαs variant XLαs protein escapes activation-induced subcellular redistribution and is able to provide sustained signaling. J Biol Chem (2011) 0.85
C-terminal analogues of parathyroid hormone: effect of C-terminus function on helical structure, stability, and bioactivity. Biochemistry (2006) 0.84
Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol Pharmacol (2009) 0.83
The Institute of Medicine's report on non-heart-beating organ transplantation. Kennedy Inst Ethics J (1998) 0.83
G protein-coupled receptor modulation with pepducins: moving closer to the clinic. Ann N Y Acad Sci (2011) 0.82
Residue 19 of the parathyroid hormone (PTH) modulates ligand interaction with the juxtamembrane region of the PTH-1 receptor. Biochemistry (2002) 0.82
Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism. ACS Chem Biol (2014) 0.80
Ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) and nuclear factor-κB (NF-κB): a feed-forward loop for systemic and vascular inflammation. J Biol Chem (2013) 0.80
Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor. Mol Endocrinol (2015) 0.80
Immunoassays for the detection of parathyroid hormone. J Bone Miner Res (2002) 0.80
Backbone-methylated analogues of the principle receptor binding region of human parathyroid hormone. Evidence for binding to both the N-terminal extracellular domain and extracellular loop region. J Biol Chem (2005) 0.79
Toward parathyroid hormone minimization: conformational studies of cyclic PTH(1-14) analogues. Biochemistry (2004) 0.79
Chemistry as an expanding resource in protein science: fully synthetic and fully active human parathyroid hormone-related protein (1-141). Angew Chem Int Ed Engl (2012) 0.79
Engineering of therapeutic polypeptides through chemical synthesis: early lessons from human parathyroid hormone and analogues. J Am Chem Soc (2012) 0.78
Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand. Endocrinology (2011) 0.77
Residue 19 of the parathyroid hormone: structural consequences. Biochemistry (2002) 0.77
Switching modes for G protein-coupled receptor activation. Nat Chem Biol (2006) 0.77
Functional evidence for an intramolecular side chain interaction between residues 6 and 10 of receptor-bound parathyroid hormone analogues. Biochemistry (2003) 0.77
Cooperative interaction of arginine-19 and the N-terminal signaling domain in the affinity and potency of parathyroid hormone. Biochemistry (2004) 0.76
Molecular mechanisms of receptor activation: real-time analysis by fluorescence resonance energy transfer. Auton Autacoid Pharmacol (2003) 0.76
Heterologous downregulation of vasopressin type 2 receptor is induced by transferrin. Am J Physiol Renal Physiol (2012) 0.76
Commentary: clear thinking and open discussion guide IOM's report on organ donation. J Law Med Ethics (1998) 0.75
Acceptance remarks. J Clin Invest (2013) 0.75
Corrigendum: SIKs control osteocyte responses to parathyroid hormone. Nat Commun (2017) 0.75
Proceedings of the 2011 Santa Fe Bone symposium. J Clin Densitom (2012) 0.75
Supplement on primary hyperparathyroidism. J Clin Densitom (2013) 0.75
A conversation with John T. Potts Jr. Interview by Ushma S. Neill. J Clin Invest (2013) 0.75